Results 91 to 100 of about 25,871 (216)

Opsoclonus‐Myoclonus‐Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Ana Silvia Sobreira Lima Verde   +6 more
wiley   +1 more source

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 10, Page 2114-2123, October 2026.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak   +4 more
wiley   +1 more source

Editorial: Neuroimmunology in Africa

open access: yesFrontiers in Immunology, 2023
Willias Masocha   +4 more
doaj   +1 more source

The interaction of neuroimmunology, neuromodulator, and neurotransmitter with nociceptor and MAPK signaling

open access: yesBali Journal of Anesthesiology, 2019
Physiological pain is a protection mechanism against tissue damage or potential tissue damage. Inflammation pain is followed by tissue damage due to temperature, mechanical and chemical stimuli which increase crosstalk between neuron nociceptor, immune ...
Dewa Ayu Mas Shintya Dewi, Made Wiryana
doaj   +1 more source

Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?

open access: yesAlzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Lieza G Exalto   +6 more
wiley   +1 more source

Uveitis in patients with multiple sclerosis

open access: yes, 2012
11th International Congress of Neuroimmunology (ISNI) -- NOV 04-08, 2012 -- Boston, MAWOS: 000312764800091…European Sch Neuroimmunol, Int Soc Neuroimmunol ...
Kurtuncu, Murat   +6 more
core  

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

open access: yesAnnals of Neurology, Volume 100, Issue 4, Page 808-823, October 2026.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello   +20 more
wiley   +1 more source

A clear look at the neuroimmunology of multiple sclerosis and beyond

open access: yes, 2012
The term neuroimmunology was first coined to refer to a generic involvement of the immune system in the pathogenesis of neurological diseases, particularly of the central nervous system.
E. Mix   +5 more
core   +1 more source

Research priorities for neuroimmunology: identifying the key research questions to be addressed by 2030 [PDF]

open access: yes
Neuroimmunology in the broadest sense is the study of interactions between the nervous and the immune systems. These interactions play important roles in health from supporting neural development, homeostasis and plasticity to modifying behaviour ...
Mondelli, V   +16 more
core   +1 more source

Real‐World Clinical Outcomes and Corticosteroid Tapering in Telitacicept‐Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History

open access: yesBrain and Behavior, Volume 16, Issue 10, October 2026.
ABSTRACT Introduction Ocular myasthenia gravis (OMG) is an autoantibody‐mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid‐tapering outcomes in OMG remain unexamined.
Siyu Xie   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy